Xenetic Biosciences, Inc. Overview
Pro stress-test →Xenetic Biosciences is a biopharmaceutical company focused on advancing immune-oncology technologies to treat cancers, with a proprietary DNase platform designed to improve outcomes of existing treatments by targeting neutrophil extracellular traps (NETs) involved in cancer progression. The company is advancing toward clinical proof-of-concept studies in multiple indications, particularly pancreatic cancer and other solid tumors.
Strategic Profile
Pro stress-test →The company is focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic has expanded its strategic partnership with The Scripps Research Institute and collaborates with PeriNess to initiate clinical studies exploring DNase I combinations with CAR T-cells for lymphoma and with FOLFIRINOX for pancreatic cancer.
Competitive Landscape
Pro stress-test →Xenetic has partnerships with multiple biotechnology and pharmaceutical companies to develop its proprietary PolyXen drug delivery platform. The company competes in the crowded CAR-T and immunotherapy space but differentiates through its NETs-targeting DNase platform designed to enhance existing cancer treatments. Key competitors include established CAR-T developers (Novartis, Gilead/Kite, Juno Therapeutics) and other NET-targeting immunotherapy developers.
Industry Context
Xenetic Biosciences, Inc. operates in Biopharmaceutical - Immuno-Oncology & CAR-T Cell Therapy.
Key facts
Headquarters: Framingham, Massachusetts · Revenue: $2.5M (2024)